Business Overview: Lantheus Holdings, Inc. (NASDAQ: LNTH)

---

Executive Summary

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company that develops, manufactures, and sells diagnostic and therapeutic agents used in nuclear medicine imaging and, increasingly, targeted radiotherapy. Headquartered in Bedford, Massachusetts, Lantheus describes its mission as helping clinicians "find, fight, and follow disease."

Lantheus matters because it holds the dominant commercial position in PSMA PET imaging for prostate cancer through its flagship product PYLARIFY, the single most important growth driver in nuclear medicine over the past several years. For full-year 2025, the company reported $1.54 billion in total revenue, $233.6 million in GAAP net income, and a gross margin of roughly 61%, while actively reshaping its portfolio through two sizable 2025 acquisitions (Evergreen Theragnostics and Life Molecular Imaging) and the divestiture of its legacy SPECT imaging business.

---

1. Core Business Model & How They Work

Lantheus manufactures radioactive diagnostic and therapeutic agents and distributes them to U.S. hospitals, independent imaging centers, and government facilities, with international sales handled through direct operations and third-party distributors. Because many of its isotopes have short half-lives, manufacturing and distribution logistics are as important to the business model as the underlying chemistry.

[ Isotope Production (F-18/Ga-68 Manufacturing Network - "PMFs") ]
   ➡️ [ Radiopharmaceutical Formulation & QC ]
   ➡️ [ Time-Sensitive Regional Distribution (short isotope half-life) ]
   ➡️ [ Hospitals / Imaging Centers administer dose to patient ]
   ➡️ [ Per-Dose Revenue + Licensing/Milestone Income from Partners ]

Key Operational Drivers

1. Regional Manufacturing Network ("PMFs"): Because PYLARIFY's F-18 isotope decays quickly, Lantheus relies on a distributed network of production/manufacturing facilities positioned close to end customers — a logistics-heavy infrastructure that is slow and expensive for a new entrant to replicate nationally.
2. Platform Expansion via M&A: In 2025, Lantheus acquired Evergreen Theragnostics ($276.4M upfront, up to $727.5M in additional milestones) to add CDMO/radiotherapeutic manufacturing capability, and Life Molecular Imaging ($352.9M upfront, up to $400.0M in earn-outs) to add the Alzheimer's-imaging agent Neuraceq — both deals aimed at diversifying beyond PYLARIFY/DEFINITY concentration.
3. Portfolio Pruning: Lantheus sold its legacy SPECT imaging business to SHINE (effective January 1, 2026, for up to $155.0 million), reallocating capital and management focus toward higher-growth PET and theranostic assets.
4. Partnered Revenue Streams: Beyond direct product sales, Lantheus earns royalties and milestones from partners such as GE HealthCare (which licenses the Flyrcado tau-imaging-adjacent agent) and from RELISTOR sales-based milestones, plus digital AI solutions (aBSI, aPROMISE/PYLARIFY AI) that complement its imaging agents.

---

2. Business Segments

Lantheus organizes its disclosure around product/revenue categories rather than classic geographic or divisional segments:

                         ┌─────────────────────────────────────┐
                         │          Lantheus Holdings            │
                         └───────────────────┬─────────────────────┘
          ┌─────────────────────┬────────────┴───────────┬───────────────────────┐
          ▼                     ▼                        ▼                       ▼
  Radiopharmaceutical    Precision Diagnostics    Strategic Partnerships    Pipeline / R&D
  Oncology                (DEFINITY ultrasound     & Other Revenue          (MK-6240, LNTH-2501,
  (PYLARIFY - PSMA PET     agent; Neuraceq          (Flyrcado royalties,     NAV-4694, RM2 pair,
  for prostate cancer)     beta-amyloid PET)         Evergreen CDMO,         new Pylarify formulation)
                                                      RELISTOR milestones,
                                                      aBSI/aPROMISE AI tools)

Radiopharmaceutical Oncology

Anchored by PYLARIFY, a PSMA PET imaging agent used to detect and stage prostate cancer, distributed through a network of F-18 production/manufacturing sites (PMFs). This is Lantheus's single largest revenue driver.

Precision Diagnostics

Led by DEFINITY, an ultrasound enhancing agent used in echocardiography (over 80% share of its U.S. category as of year-end 2025), plus Neuraceq, a beta-amyloid PET imaging agent for Alzheimer's disease evaluation added through the Life Molecular acquisition. The legacy SPECT business, divested to SHINE effective January 1, 2026, previously sat in this category.

Strategic Partnerships and Other Revenue

Includes digital solutions (aBSI, aPROMISE/PYLARIFY AI), royalties and milestone payments from partners (e.g., Flyrcado, licensed to GE HealthCare), RELISTOR sales-based milestones, and contract development/manufacturing (CDMO) services from the newly acquired Evergreen business.

---

3. Product Portfolio

---

4. Competitive Landscape

• PYLARIFY (PSMA PET imaging): Competes against Telix Pharmaceuticals (Illuccix) and Blue Earth Diagnostics, a Bracco company (Posluma), both offering competing PSMA PET agents, as well as against non-PSMA imaging modalities. Novartis, while primarily a PSMA-targeted radiotherapy competitor (Pluvicto) rather than a direct imaging rival, is reshaping the broader PSMA care pathway. Generic/biosimilar-style entry risk rises after PYLARIFY's NCE exclusivity expires in May 2026.
• DEFINITY (ultrasound enhancing agents): Competes against GE HealthCare (Optison) and Bracco (Lumason), with Lantheus holding the largest U.S. share.
• Neuraceq (beta-amyloid PET): Competes against Eli Lilly (Amyvid) and GE HealthCare (Vizamyl) in the Alzheimer's imaging category.

                SINGLE AGENT RISK                   DIVERSIFIED PORTFOLIO
              ┌─────────────────────────────────────────────────────┐
HIGH MARKET   │  PYLARIFY (pre-2025: nearly all    Post-Evergreen/Life │
SHARE         │  growth concentrated here)          Molecular: broader  │
              │                                     oncology+neuro+CDMO│
              ├─────────────────────────────────────────────────────┤
LOWER MARKET  │  Telix Illuccix, Blue Earth         Competitors' own    │
SHARE         │  Posluma (PSMA challengers)         diversified imaging │
              │                                     portfolios (GE, Lilly)│
              └─────────────────────────────────────────────────────┘

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

• PSMA PET market leadership: PYLARIFY's first-mover scale and distribution through a dedicated regional manufacturing network gave Lantheus a commanding share of PSMA PET imaging well before close competitors reached the market.
• Isotope logistics infrastructure: The PMF network required to distribute short-half-life F-18 agents nationally is slow and capital-intensive to replicate, acting as a practical barrier to rapid competitive entry even after patent protection narrows.
• Active portfolio reshaping: The 2025 Evergreen Theragnostics and Life Molecular acquisitions, combined with the SPECT divestiture, show management actively diversifying revenue away from PYLARIFY concentration and into adjacent therapeutics/CDMO and neurology-imaging growth areas.
• DEFINITY's durable, high-share franchise: Over 80% U.S. share in ultrasound enhancing agents provides a stable, less patent-cliff-exposed cash flow base alongside the higher-growth, higher-risk oncology business.

Risks

• PYLARIFY exclusivity cliff: NCE exclusivity expires in May 2026, opening the door to intensified competition from Telix, Blue Earth/Bracco, and potential generic-style entrants right as PYLARIFY sales were already down 6.5% year over year in 2025.
• Revenue concentration: PYLARIFY and DEFINITY together represent roughly 85% of 2025 revenue, meaning any competitive or regulatory setback in either product has an outsized effect on overall results.
• Patent litigation overhang: An ANDA-related Paragraph IV patent dispute with Novartis over PNT2003 remains pending in court, with an uncertain outcome.
• Pipeline/regulatory timing risk: Several near-term catalysts (MK-6240, LNTH-2501, the new PYLARIFY formulation) all carry 2026 PDUFA dates — a cluster of binary regulatory events that could individually disappoint.
• Leadership transition: Longtime CEO Brian Markison retired effective December 31, 2025, with Board Chair Mary Anne Heino stepping in as CEO on January 1, 2026, introducing a degree of execution uncertainty during a pivotal competitive period.

---

6. Financial Overview

---

7. Summary Conclusion

Lantheus built a genuine, if narrowing, moat in PSMA PET imaging by combining first-mover scale with a hard-to-replicate regional isotope-manufacturing network, and it is using that cash flow — supplemented by the DEFINITY franchise — to actively diversify into theranostics, neurology imaging, and CDMO services ahead of PYLARIFY's May 2026 exclusivity cliff. The company's near-term trajectory now hinges on whether its newly acquired Neuraceq and Evergreen businesses, plus a cluster of 2026 pipeline approvals, can offset intensifying PSMA competition from Telix and Blue Earth Diagnostics quickly enough to prevent PYLARIFY's 2025 revenue decline from accelerating.